Abstract:
The present invention relates to the preparation, structure and properties of water-soluble polymer therapeutics based on cytarabine derivatives, intended primarily for the treatment of leukaemias and non-Hodgkin's lymphomas in human medicine. Cytarabine is attached to the polymer backbone via amide bond to an amino acid or oligopeptidic sequence situated within the polymer side chain. The structure of cytarabine acylamides enables the stability of the whole polymeric system during blood circulation, and thus its sufficient accumulation in the neoplastic tissue, wherein the drug is allowed to be released hydrolytically. The present invention further relates to the polymeric cytostatics, which is stable in blood stream, to the pharmaceutical composition and use thereof in medicine.
Abstract:
The present invention provides a liquid polymeric wound dressing composition having an anti- inflammatory effect, comprising a polymer network comprising at least one type of structural units derived from sterically hindered amines, at least one type of structural units derived from alkyloxysilanes and at least one type of structural units derived from alkylsiloxanes.
Abstract:
The present invention relates to a method of preparation of a substrate surface containing carboxybetaine groups with bound bioactive substances, having resistance to undesirable deposition of biological media components on the substrate surface, comprising the steps of chemical activation of carboxybetaine groups on the surface of the substrate by converting the carboxybetaine carboxyl group into an active ester, covalent binding of a bioactive substance to some of the active esters, and reaction of the product from the previous step with an acid of general formula (I) NH 2 -(CH 2 -CH 2 -0) n -CH 2 -COOH, where n = 1 to 4, wherein the acid of general formula (I) reacts with those active esters, which have not undergone covalent bonding of the bioactive substance.
Abstract:
The present invention relates to the preparation and use of copolymers composed of N-(2- hydroxypropyl) methacrylamide (HPMAA) and carboxybetaine methacrylamide (CBMAA). The invention further describes polymer brushes having structure I S-R-polymer (I) wherein S is a substrate; R is a residue of a polymerization initiator or a RAFT agent bound to the substrate; and "polymer" is the copolymer of N-(2-hydroxypropyl) methacrylamide and carboxybetaine methacrylamide Furthermore, production of these polymer brushes, containing random or block copolymers grafted to or from a substrate is described. The copolymer brushes are suitable for protecting substrates from deposition and/or adhesion of biological substances, and/or against thrombus formation. The brushes functionalized by covalent attachment of bioactive substances to CBMAA monomer units are particularly suitable for specific interaction with target biological substances which is not affected by nonspecific deposition of non-target compounds.
Abstract:
The present invention provides a composition for stabilization of polyethylene, consisting of a first component selected from the group comprising tocoferols, tocotrienols and 5 mixtures thereof, and of a second component which is a tetracycline antibiotic. Furthermore, the invention provides polyethylene comprising this mixture, preferably in an amount of at least 200 ppm, methods of production thereof, and implants for human or veterinary medicine comprising said stabilized polyethylene.
Abstract:
The present invention relates to water-soluble high-molecular-weight polymer drug carriers and their conjugates with drugs, derived from dendrimers of the amidoamine and 2,2-bis(hydroxymethyl)propanoic types, the amino and hydroxy end groups of which are attached to semitelechelic copolymers of N-(2 hydroxypropyl)methacrylamide (HPMA) through biodegradable spacers. The polymer carriers and conjugates enable targeted transport notably of anticancer drugs into solid tumors in which biodegradation, the associated controlled drug release and subsequent elimination of polymer carrier from the organism are provided. The polymer carrier conjugated with a cancerostatic for use in targeted therapy of human tumors.
Abstract:
The invention concerns contact and intraocular lenses formed by a polymer from 89 to 99.6 % of vinyl monomers, 0.2 to 6 wt.% of polymerizable absorbers of ultraviolet radiation, 0.1 to 3 wt.% of a crosslinker and 0.1 to 2 wt.% of a polymerization initiator. As vinyl monomers, the monomers are used selected from the group comprising alkyl acrylates and methacrylates, hydroxyalkyl acrylates and methacrylates, fluoroalkyl acrylates and methacrylates, (alkyloxy)alkyl acrylates and methacrylates, (acyloxy)alkyl acrylates and methacrylates, (acylamino)alkyl acrylates and methacrylates, (alkylsulfinyl)alkyl acrylates and methacrylates, (alkylsulfonyl)alkyl acrylates and methacrylates, tris(alkyloxy)silylalkyl acrylates and methacrylates, N-vinylpyrrolidone, N-vinylpiperidone and their combinations. As polymerizable absorbers of ultraviolet radiation, substances selected from the group of substances comprising substances of general formula (I) or (II) are used where R , R are hydrogen, acryloyloxy, methacryloyloxy, (acryloyloxy)alkyloxy, (methacryloyloxy)alkyloxy, 3-(methacryloyloxy)-2-hydroxypropyloxy, vinyl, allyloxy, (acryloylamino)methyl, (methacryloylamino)methyl groups, R , R are hydrogen, hydroxy, halogen, cyano, alkyloxy, alkyl, (alkyloxy)alkyl, hydroxyalkyl groups, the alkyls being alkyl groups with 1 to 4 carbon atoms or (III) or (IV), where R is acryloyl or methacryloyl group, or their mixture. As cross-linking agents, substances are used selected from the group comprising acrylic and methacrylic esters of dihydric alcolhols, amino alcohols, amines, allyl acrylates and methacrylates and diallyl esters of dicarboxylic acids and as polymerization initiators, common azo and peroxy initiators and initiators cleavable by UV radiation.
Abstract:
The invention pertains to new medical forms of pharmaceutics with prolonged effect applied in eye medicine, which are formed by a pregel or gel based on the copolymers of 2-(2-carboxybenzoyloxy)ethyl methacrylate with methacrylate comonomers selected from the group comprising methyl methacrylate and butyl methacrylate, the carboxyl groups of which are at least in part modified and/or neutralized with at least one pharmaceutically active substance and/or neutralized with Na and/or K ions and/or organic bases and which contains, if it is desired, encapsulated another pharmaceutically active substances. One of the methods for the preparation of these new medical forms consists in at least partial neutralization of functional carboxyl groups of the latex, based on the copolymers of 2-(2-carboxybenzoyloxy)ethyl methacrylate with methacrylate comonomers selected from the group comprising methyl methacrylate and butyl methacrylate, with a basic pharmaceutically active substance and/or sodium hydroxide and/or potassium hydroxide and/or organic bases. The scope of the invented solution comprises also further methods for the preparation of the medical forms according to the invention.
Abstract:
Title of the invention: Method for preparation of polymeric materials The invention provides a method of preparation of a polymeric material, wherein at least one cyclic monomer is combined with hydrated layered double hydroxide of formula [M 2+ 1-xM 3 +x(OH)2(A m -)x/m], wherein A m is an m-valent anion, M 2+ is a divalent metal cation and M 3+ is a trivalent metal cation, the value x is in the range of 0.20
Abstract:
Macromolecular conjugates for isolation, immobilization and visualization of proteins The invention provides a synthetic macromolecular conjugate for selective interaction with proteins, comprising a synthetic copolymer, and at least one binding group and at least one further group selected from an affinity tag and an imaging probe, said at least one binding group and at least one further group being bound via covalent bond to said synthetic copolymer. The macromolecular conjugate is suitable in particular for identification, visualization, quantification or isolation of proteins and/ or cells. HPMA copolymer, i.e.poly(HPMA-co-Ma-β-Ala-TT), a copolymer prepared by conventional solution radical polymerization or controlled radical copolymerization (e.g. RAFT copolymerization, reversible addition-fragmentation chain-transfer) of N-(2- hydroxypropyl) methacrylamide (HPMA) and 3-(3-methacrylamidopropanoyl) thiazolidine-2-thione (Ma-P-Ala-TT) can be preferably used as the basic copolymer.